TRINETRA › Sectors › Healthcare
Anlon Healthcare Limited (AHCL) — share price, P/E and fundamentals
Anlon Healthcare Limited (NSE: AHCL) closed at ₹25.89 on 30 Oct 2026, +103.9% over one year, against a 52-week range of ₹10.37 – ₹37.24.
In the quarter ended 30 Sept 2026 (consolidated, filed 29 Oct 2026) it reported revenue of ₹106 cr and net profit of ₹13 cr, a 12.7% net margin; revenue grew 102.3% and profit grew 88.6% year on year.
On four consecutive filed quarters its trailing P/E is 49.5.
From the balance sheet dated 30 Sept 2026: return on equity 20.8%, ROCE 31.7%, debt-to-equity 0.28, Piotroski F-score 5 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 48% of 64 sector peers; PBT margin higher than 67% of 64 sector peers; ROE higher than 77% of 64 sector peers.
Key figures
| Last close | ₹25.89 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -9.6% / +63.1% / +103.9% |
| 52-week low – high | ₹10.37 – ₹37.24 |
| Market capitalisation | ₹1,376 cr |
| Trailing P/E | 49.5 |
| Price / book | 6.18 |
| EV / EBITDA | 29.5 |
| Earnings yield | 2.0% |
| TTM EPS | ₹0.52 |
| TTM net profit | ₹28 cr |
| Quarter revenue | ₹106 cr |
| Quarter net profit | ₹13 cr |
| Net margin | 12.7% |
| Revenue growth (YoY) | +102.3% |
| Profit growth (YoY) | +88.6% |
| Return on equity | 20.8% |
| ROCE | 31.7% |
| Debt / equity | 0.28 |
| Current ratio | 2.54 |
| Free cash flow | ₹-36 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹14.5 cr |
Against Healthcare peers
| Metric | AHCL | Peer median | Percentile |
|---|---|---|---|
| Net margin | 12.66 | 12.89 | 48 |
| PBT margin | 22.23 | 17.68 | 67 |
| ROE | 20.77 | 13.87 | 77 |
| ROCE | 31.65 | 17.26 | 86 |
| Debt / equity | 0.28 | 0.11 | 69 |
| FCF margin | -18.60 | -0.87 | 13 |
| Cash conversion | -0.31 | 1.25 | 2 |
| Trailing P/E | 49.52 | 43.26 | 55 |
Questions
What is the P/E ratio of Anlon Healthcare Limited?
Anlon Healthcare Limited's trailing P/E is 49.5, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026.
What were Anlon Healthcare Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Anlon Healthcare Limited reported revenue of ₹106 cr and net profit of ₹13 cr (consolidated), filed with the exchange on 29 Oct 2026.
What is Anlon Healthcare Limited's ROE?
Return on equity is 20.8% based on the balance sheet dated 30 Sept 2026.
Does Anlon Healthcare Limited have debt?
Debt-to-equity is 0.28 on the balance sheet dated 30 Sept 2026.
What is AHCL's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, AHCL traded between ₹10.37 and ₹37.24.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.